


Procedure file

Basic information	
COD - Ordinary legislative procedure (ex-codecision procedure) Regulation	2003/0311(COD) Procedure lapsed or withdrawn
European Monitoring Centre for Drugs and Drug Addiction EMCDDA	
Subject 8.40.08 Agencies and bodies of the EU	

Key players	
European Parliament	
Council of the European Union	
European Commission	Commission DG Justice and Consumers
	Commissioner

Key events			
18/12/2003	Legislative proposal published	COM(2003)0808	Summary
09/02/2004	Committee referral announced in Parliament, 1st reading		
06/04/2004	Vote in committee, 1st reading		
05/04/2004	Committee report tabled for plenary, 1st reading	A5-0248/2004	
20/04/2004	Debate in Parliament		
21/04/2004	Decision by Parliament, 1st reading	T5-0336/2004	Summary
22/09/2004	Amended legislative proposal for reconsultation published	SGS4/10632	
31/08/2005	Additional information		Summary
17/03/2006	Additional information		Summary

Technical information	
Procedure reference	2003/0311(COD)
Procedure type	COD - Ordinary legislative procedure (ex-codecision procedure)
Procedure subtype	Recast
Legislative instrument	Regulation
Legal basis	EC Treaty (after Amsterdam) EC 152
Stage reached in procedure	Procedure lapsed or withdrawn

Documentation gateway

Legislative proposal	COM(2003)0808	19/12/2003	EC	Summary
Committee report tabled for plenary, 1st reading/single reading	A5-0248/2004	06/04/2004	EP	
Text adopted by Parliament, 1st reading/single reading	T5-0336/2004 OJ C 104 30.04.2004, p. 0423-0632 E	21/04/2004	EP	Summary
Amended legislative proposal for reconsultation	SGS4/10632	23/09/2004	CSL	
Economic and Social Committee: opinion, report	CES1437/2004 OJ C 120 20.05.2005, p. 0078-0079	27/10/2004	ESC	

Additional information

European Commission

[EUR-Lex](#)

European Monitoring Centre for Drugs and Drug Addiction EMCDDA

PURPOSE : to recast the Regulation on the European Monitoring Centre for Drugs and Drug Addiction. **PROPOSED ACT :** Council Regulation. **CONTENT :** Council Regulation 302/93/EEC on the establishment of a European Monitoring Centre for Drugs and Drug Addiction has been amended three times. New amendments are needed in order in particular to extend the Centre's role to include the examination of new trends in drug use involving the combination of legal and illegal substances, to confer evaluation tasks on the Centre and to adapt the operation of the Centre's Management Board and Scientific Committee to take account of enlargement. It therefore seemed appropriate in the interests of clarity to recast the Regulation. The proposed amendments can be divided into the following categories: - those designed to boost the Centre's role, in particular to take account of new drug use patterns, especially among young people, who increasingly tend to combine unlawful substances with lawful substances such as alcohol, and to enable the Centre to devise indicators for evaluating drugs policies and strategies implemented in the European Union. In addition, it is proposed that the EMCDDA's collection, registration and analysis work must also cover data on emerging trends in poly-drug use, including the combined use of legal and illegal psychotropic substances. Furthermore, as regards improving the data comparison methodology, it requires the EMCDDA to devise indicators for evaluating drugs policies and strategies implemented in the European Union. The scope of the Centre's technical assistance is extended to all countries authorised by a European Council to take part in Community programmes and agencies; - those designed to adapt the operation of the EMCDDA's bodies in order to take account of enlargement. The Regulation sets up a Steering Committee to assist the Management Board. A review of the composition of the Centre's Scientific Committee is also proposed. Moreover, the role of vice-chairman is created. Since the European Parliament is the discharge authority and in order to avoid any conflict of interests during the annual discharge procedure, it is proposed that the European Parliament no longer be represented on the EMCDDA's management board. However, this provision should enter into force only when the current term of the members representing the European Parliament expires. The non-voting status of the Management Board members representing countries which have concluded agreements pursuant to Article 17 is specified. It provides for the hearing of the Director before the European Parliament. The Scientific Committee is to be composed of 18 members appointed by the EMCDDA's Management Board, instead of one representative per Member State. This provision has been introduced in order to prevent the Scientific Committee becoming too big after enlargement to the detriment of its efficiency; - those designed to harmonise the EMCDDA Regulation with the Regulation on the new Community regulatory agencies; - those codifying the three amendments to the basic Regulation already adopted by the Council; - those designed to remove a number of uncertainties which emerged when the initial Regulation was applied. In particular, this concerns the reference to the Reitox focal points, instead of the specialised centres. It should be noted that the proposal requires external evaluation reports of the Centre's work which are to be conducted every five years. On the basis of this evaluation, the Commission may, if appropriate, present proposals with a view to amending the EMCDDA Regulation. **FINANCIAL IMPLICATIONS :** there shall be no financial implications on the European Union's budget.?

European Monitoring Centre for Drugs and Drug Addiction EMCDDA

The European Parliament adopted a resolution drafted by Ozan CEYHUN (PES, D) by 273 votes in favour, 225 against and 6 abstentions on the European Monitoring Centre for Drugs and Drug Addiction. The main amendments were as follows: - Parliament deleted the provisions stating that it no longer be represented on the EMCDDA's Management Board. Instead Parliament provided that two Members of the European Parliament should represent it on the Management Board; - it also deleted the provisions relating to the establishment of a Steering Committee; - Parliament emphasized the importance of the evaluation of trends in consumption and supply; - Regulation 45/2001/EC shall apply to the processing of personal data by the Centre; - the seat of the Centre shall remain in Lisbon.?

European Monitoring Centre for Drugs and Drug Addiction EMCDDA

On 21 April 2004, Parliament delivered its opinion on this proposal, in accordance with the procedure foreseen by Article 308 of the Treaty. However, following considerable debate amongst the Member States in Council, it was decided that the legal basis for this particular proposal should be changed and that the European Parliament should be re-consulted in accordance with the new legal basis ? in other words Article 152, co-decision. Accordingly, the Commission is submitting a new proposal based on Article 152 of the Treaty (COM(2005)0399 ? 2005/0166 COD), which will replace the previous proposal. Procedure 2003/0311 has thus been terminated.

European Monitoring Centre for Drugs and Drug Addiction EMCDDA

As announced in Official Journal C 64 of 17 March 2006, the Commission decided to withdraw this proposal, which had become obsolete.